US OptionsDetailed Quotes
ITOS250117C20000
- 0.25
- 0.000.00%
15min DelayTrading Sep 18 11:24 ET
0.00High0.00Low
0.00Open0.25Pre Close0 Volume210 Open Interest20.00Strike Price0.00Turnover264.71%IV179.50%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.1308Delta0.0426Gamma28.98Leverage Ratio-0.0210Theta0.0005Rho3.79Eff Leverage0.0040Vega
ITeos Therapeutics Stock Discussion
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Thursday, 12th December at 8:55 am
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts
- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrat...
$ITeos Therapeutics (ITOS.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Pearson (PSO.US)$
$UnitedHealth (UNH.US)$
$Option Care Health (OPCH.US)$
$Procter & Gamble (PG.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Datadog (DDOG.US)$
$Pearson (PSO.US)$
$Procter & Gamble (PG.US)$
$Option Care Health (OPCH.US)$
$UnitedHealth (UNH.US)$
No comment yet